H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 21.28 HKD 1.04% Market Closed
Market Cap: 18.6B HKD

Relative Value

The Relative Value of one HUTCHMED (China) Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 21.28 HKD, HUTCHMED (China) Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HUTCHMED (China) Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
75
vs Industry
29
Median 3Y
4.3
Median 5Y
4.9
Industry
2.6
Forward
3.9
vs History
32
vs Industry
13
Median 3Y
-5.8
Median 5Y
-8.4
Industry
21.6
Forward
27.2
vs History
vs Industry
26
Median 3Y
-7.8
Median 5Y
-10
Industry
16.5
vs History
vs Industry
26
Median 3Y
-10.7
Median 5Y
-17.6
Industry
22.5
vs History
91
vs Industry
21
Median 3Y
3.7
Median 5Y
3.8
Industry
2.3
vs History
89
vs Industry
38
Median 3Y
2.9
Median 5Y
3.4
Industry
2.9
Forward
1.8
vs History
91
vs Industry
28
Median 3Y
6.4
Median 5Y
8.3
Industry
5.5
vs History
vs Industry
3
Median 3Y
-21.6
Median 5Y
-19.9
Industry
13
Forward
-83.3
vs History
vs Industry
2
Median 3Y
-19.7
Median 5Y
-18.5
Industry
16.6
Forward
38.5
vs History
vs Industry
33
Median 3Y
-5.6
Median 5Y
-7.2
Industry
15.8
vs History
vs Industry
24
Median 3Y
-9
Median 5Y
-13.1
Industry
19.1
vs History
91
vs Industry
17
Median 3Y
5.1
Median 5Y
5.4
Industry
1.9

Multiples Across Competitors

Competitors Multiples
HUTCHMED (China) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
HUTCHMED (China) Ltd
HKEX:13
18.6B HKD 4 5.1 -148.7 -56.5
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
252.3B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 4.8 29.7 108 158
CH
Novartis AG
SIX:NOVN
202.4B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
249.5B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average P/E: 21.6
5.1
-18%
N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average EV/EBITDA: 438.7
Negative Multiple: -148.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average EV/EBIT: 1 881.1
Negative Multiple: -56.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3